Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease

ORYZON announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific Lysine Specific Demethylase 1 (LSD1) and Monoamine oxidase B (MAO-B) inhibitor for the treatment of Huntington disease (HD). These inhibitors increased survival time and improved several behavioral and motor parameters in different transgenic animal models.

Click here to see the full Press Release.